Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-73

	Column 1	Column 2	Column 3	Column 4	Column 5
1	year	row	usa	world	europe
2	2022	83<4.4%>	275<3.2%>	391<20%>	33<70.5%>
3	2021	90<5.8%>	253+6.5%	455<12.3%>	112<40.6%)
4	2020	103+2.9%	246+17.9%	536+12.2%	187+10.6%
5	2019	78+17.7%	212+12.3%	458+11%	168+7%

So the figures have come in for full year (calendar) 2023

Sales of Jevtana (Cabazitaxel) by Sanofi for calendar year 2023 decreased 14.8% to €$320 million due to generic competition in Europe and lower sales in the U.S., reflecting increased competition. This is equivalent to AU$530 million

You can see in column four for the periods 2019 - 2022 generic competition has affected sales of jevtana

Every year the generic competition is eating into the sales of jevtana

There is a strong business case for Sanofi to take Starpharma's improved version Dep® Cabazitaxel